Par Drugs and Chemicals Limited
ListedSMEHealthcare & Pharmaceuticals · NSE
Par Drugs and Chemicals Limited, incorporated in 1999 and based in Gujarat, is engaged in the manufacturing and development of active pharmaceutical ingredients (APIs) and fine chemicals for both domestic and international markets. Its APIs are used in tablets, capsules, and other finished dosages, and it also produces various antacid molecules. The company operates two manufacturing facilities in Ankleshwar and Bhavnagar, Gujarat, and offers a portfolio of 6 fine chemicals and 12 API products sold across 17 countries. Key customers include Dabur India Ltd, Meyer Organics Pvt. Ltd, Cadila Healthcare Ltd., Cipla Ltd, and Pfizer Ltd. For fiscal 2018, international sales accounted for 86.88% of total revenue, while domestic sales contributed 13.12%. The company maintains a testing laboratory to ensure quality standards and provides drying operations to convert liquid products into powders for its clients.
Price Band
₹51
Issue Size
₹9.00 Cr
Lot Size
2000 shares
GMP
—
Est. Listing
₹51
at current GMP
Subscribed
—
Open
3 May 2019
Close
8 May 2019
Allotment
13 May 2019
Refund
14 May 2019
Demat Credit
15 May 2019
Listing
16 May 2019
Last updated 12 days ago
Live Grey Market Premium
Par Drugs and Chemicals Limited GMP Today
Last updated: 19 Oct 2026
Current Premium
₹00.0%
Issue Price (Upper)
₹51
Band: ₹51
Estimated Listing Price
₹51
Upper price + GMP
Lot Size
2000 shares
Min investment ₹1,02,000
Estimated Profit / Lot
₹0
2000 × ₹0
Par Drugs and Chemicals Limited GMP Historical Trend
GMP History
Grey Market Premium trend
—
▲ 0 today
Updated less than a minute ago
Estimated Listing Price
| Date | GMP (₹) | GMP % | Est. Listing |
|---|---|---|---|
| 31 Oct 2026 | — | 0.0% | ₹51 |
| 30 Oct 2026 | — | 0.0% | ₹51 |
| 29 Oct 2026 | — | 0.0% | ₹51 |
GMP is unofficial market data. Not a guarantee of listing performance.
About Par Drugs and Chemicals Limited Public Issue & Market Profile
Par Drugs and Chemicals Limited is bringing an initial public offering (IPO) in the Healthcare & Pharmaceuticals sector with an aggregate issue size of ₹9 Crores. The shares are offered at a price band of ₹51 to ₹51 per equity share on NSE. Currently, market analysts recommend evaluating the company's financial valuation, price-to-earnings (P/E) multiple, and peer comparison prior to submitting bids.
Public Issue & Pricing Context:
The public offer consists of a fresh issue and offer-for-sale structured under SEBI regulations. Bidding is open to Qualified Institutional Buyers (QIB), Non-Institutional Bidders (NII/HNI), and Retail Individual Investors (RII). Applications can be submitted online using ASBA or UPI mandate through certified stock brokers and net banking portals.
Basis of Allotment & Listing Timeline:
Following the close of bidding on 2019-05-08, the basis of allotment is scheduled to be finalized on 2019-05-13. Investors can verify their application status online by submitting their PAN card number, Application Number, or DP Client ID on the registrar's official portal (Link Intime India Private Limited) or the BSE allotment checking window.
Frequently Asked Questions
What is Par Drugs and Chemicals Limited IPO GMP today?
The latest grey market premium for Par Drugs and Chemicals Limited IPO is ₹0, which indicates an expected listing price of ₹51.
What does Kostak Rate and Sauda mean in IPO GMP?
Kostak rate is the profit amount an investor earns by selling their entire IPO application in the grey market before allotment is finalized.
Is Grey Market Premium officially recognized?
No. GMP is an unofficial indicator discovered between dealers outside of SEBI-regulated exchanges. Actual listing price is determined by demand-supply discovery on NSE/BSE during the pre-open auction.